false
OasisLMS
Catalog
CHEST 2023 On Demand Pass
Vasoactive Therapies in Refractory Septic Shock
Vasoactive Therapies in Refractory Septic Shock
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The video discusses the use of lesser-used agents for refractory shock, specifically focusing on angiotensin II and epinephrine. The speaker discusses the pathophysiology of the renin-angiotensin system and how angiotensin II affects vasodilation and vasoconstriction. The speaker then presents the evidence for the use of angiotensin II in refractory shock, highlighting the ATAC-3 trial which showed that angiotensin II effectively increased blood pressure in patients with refractory vasodilatory shock. The speaker also discusses other studies that suggest that patients with higher renin levels or high angiotensin 1 to angiotensin 2 ratio may respond better to angiotensin II therapy. The video then shifts to discussing the use of epinephrine as a third-line vasopressor in refractory shock. The speaker acknowledges that there is no consensus on when to use epinephrine, but highlights a study that showed higher mortality in patients receiving epinephrine or dopamine as third-line vasopressors. The speaker also discusses a study that compared epinephrine to norepinephrine in the setting of cardiogenic shock and found no difference in outcomes. The speaker emphasizes the need to individualize treatment based on the patient's shock profile, including echocardiographic assessment of cardiac function and determining if LV function is adequate. The speaker suggests that in these patients, increasing the vasopressin dose or adding angiotensin II may be more effective than adding epinephrine or dopamine. However, the speaker also highlights the lack of consensus and the need for further research in this area.
Meta Tag
Category
Critical Care
Session ID
1133
Speaker
Seth Bauer
Speaker
Zainab Gandhi
Speaker
Gretchen Sacha
Speaker
Ryota Sato
Track
Critical Care
Keywords
refractory shock
angiotensin II
epinephrine
renin-angiotensin system
ATAC-3 trial
vasodilatory shock
mortality
cardiogenic shock
echocardiographic assessment
×
Please select your language
1
English